AVA 6000

51 days ago

What is Avacta worth? Certainly not today’s 33p and arguably 0p

There are some things we can all agree on. The management of Avacta (AVCT) are aggressive stock promoters. Their record of poor judgement and bad diworsification M&A deals are clear or all to see and the company will need to do a fund raise if it is to hope to progress its lead product, AVA 6000, through phase 2 trials.

119 days ago

Tom Winnifrith Bearcast No 1: Avacta demonstrates disastrous diworsification and unimpressive trial results

Bulletin Board Morons want to believe the AVA 6000 trial results out today are good. They are not. And even the biggest chatroom gerbil out there cannot deny that diworsification has been a disaster after Avacta’s (AVCT) move into diagnostics has been reversed. 

130 days ago

Avacta now sub 40p: when is the next discounted placing? Stay short, initial target 20p

The real problem Avacta (AVCT) is that trials of its lead product, the store of all the hopium in the share price, does not seem to work as Deutsche bank pointed out last Autumn.56 patients took it none were cured. If those results don’t change there is no way that AVA 6000 will make it out of phase 2 trials with Avacta, just as it failed to make it out of phase 2 a decade ago under its previous owner. That is the harsh truth chatroom gerbils have yet to accept.

203 days ago

Avacta: more lack of meaningful progress news, slowly the warnings dawn on the gerbils

The latest update from Avacta (AVCT) on its AVA 6000 product should serve as a reminder that this is going absolutely nowhere and, on that basis, just how ludicrously overpriced the stock is.